Overview

ULTIVA Post Marketing Surveillance

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
This study is a post-marketing surveillance to monitor safety and efficacy of remifentanil during various surgeries and identify SAEs, adverse drug reactions, and unexpected AEs not described as precautions or warnings and to identify prognostic factors that have an effect on the AEs and to assess effectiveness of remifentanil in real clinical practices after marketing. The subjects are patients prescribed for remifentanil by the investigators at the sites based on prescription information in normal clinical practices.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Remifentanil
Criteria
Inclusion Criteria:

- Patients requiring general anesthesia

Exclusion Criteria:

- According to precautions or warnings on PI, remifentanil should not be administered to
the following patients

- Patients with any allergic reaction to any ingredients of remifentanil or other
fentanyl analogues